Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/resp.13561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Immunology: what's new in 2023].
Rev Med Suisse
January 2024
Service d'immunologie et allergie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs and characterized by profound immune disturbances. Monoclonal antibodies such as anifrolumab, targeting type I interferon, and belimumab, targeting a cytokine that activates B-cells and plasmocytes, have shown efficacy in SLE. Voclosporine, a novel calcineurin inhibitor, improves renal outcomes when combined with standard immunosuppression in lupus nephritis.
View Article and Find Full Text PDFOmicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Front Cell Infect Microbiol
November 2023
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due to its high transmissibility, although it appears to be less pathogenic than previous strains. However, individuals with hematological malignancy (HM) and COVID-19 remain susceptible to severe infection and mortality, especially those with chronic lymphocytic leukemia (CLL) and those undergoing chimeric antigen receptor T-cell (CAR-T) treatment. Hematologists should thoroughly assess the severity of the patient's hematological disease and the potential risk of SARS-CoV-2 infection before initiating chemotherapy or immunosuppressive treatment.
View Article and Find Full Text PDFWhat's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR-T therapy.
J Clin Apher
June 2020
Laboratory Medicine and of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
[CAR-T cells in acute lymphoblastic leukemias: What's new?].
Bull Cancer
February 2020
AP-HP, université de Paris, hôpital universitaire Robert-Debré, service d'hémato-immunologie pédiatrique, 48, boulevard Serurier, 75019 Paris, France.
The approval of tisagenlecleucel in B-lineage acute lymphoblastic leukemias in 2017 in the USA and in 2018 in Europe not only opened new hopes but forced to rethink the hospital organizations around this innovation. Indeed, if these treatments are very effective in the short term, the complex logistics required imply high quality inter-center and intra-center collaboration. Hematology, intensive care unit, apheresis, neurology, cell therapy and biology laboratories, and radiology services must therefore act in a coordinated manner.
View Article and Find Full Text PDFWhat's in the CART? A decision rule to predict short-term mortality during COPD exacerbations.
Respirology
August 2019
UBC Centre for Heart Lung Innovation (HLI), St. Paul's Hospital, Vancouver, BC, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!